PRA, DSA at HLA antibodies: bakit mahalaga bago mag-kidney transplant at paano bawasan ang sensitization risk

Ang HLA o human leukocyte antigen ay mga marker sa cells na ginagamit ng immune system para makilala kung alin ang sariling tissue at alin ang foreign. Sa transplant, mahalaga ang HLA matching dahil puwedeng makabuo ang katawan ng antibodies laban sa HLA na hindi nito sarili.

Kapag may anti-HLA antibodies ang transplant candidate, tinatawag siyang sensitized. Hindi ibig sabihin nito na hindi na puwedeng ma-transplant. Ibig sabihin, kailangang mas maingat ang donor matching at crossmatch dahil may ilang donor HLA types na maaaring atakihin ng existing antibodies.

Ayon sa KDIGO, ang pangunahing sensitizing events ay blood-product transfusion, pregnancy o miscarriage, at previous transplant. Mahalaga ring sabihin sa transplant team ang mga ganitong events dahil puwedeng magbago ang antibody profile sa paglipas ng panahon.

Ang PRA ay panel reactive antibody. Historically, sinusukat nito kung gaano karaming samples mula sa isang donor panel ang nire-react ng antibodies ng patient. Sa modern transplant practice, mas ginagamit ang cPRA o calculated PRA, na estimate ng porsiyento ng donor population na inaasahang magiging incompatible dahil sa HLA antibodies ng candidate.

Halimbawa, ang mataas na cPRA ay nangangahulugang mas marami sa potential donors ang may HLA antigens na maaaring target ng antibodies mo. Hindi nito direktang sinasabi kung gaano 'kalakas' ang isang antibody at hindi ito equivalent sa iisang antibody concentration.

Kaya mahalagang basahin ang PRA/cPRA kasama ng actual HLA antibody specificities, donor HLA typing at crossmatch result—hindi bilang isang standalone number.

DSA means donor-specific antibody. Ito ay HLA antibody na tumatarget mismo sa HLA antigen na dala ng isang particular donor.

Puwedeng preformed ang DSA—nandiyan na bago transplant dahil sa previous sensitization—or de novo, ibig sabihin nabuo pagkatapos ng transplant. Ang DSA ay mahalaga dahil strongly associated ito sa antibody-mediated rejection at graft injury, lalo na kapag clinically significant at supported ng ibang findings.

Hindi lahat ng detectable DSA ay pare-pareho ang risk. Interpretation depends on antibody specificity, strength or assay characteristics, crossmatch, clinical context at transplant-center protocol.

Isipin ang cPRA bilang estimate kung gaano kalawak ang sensitization mo sa donor population. Ang DSA naman ay tanong na: 'May antibody ba akong specifically laban sa donor na ito?' Ang crossmatch ang direct compatibility test na tinitingnan kung nagre-react ang recipient serum sa donor cells.

A positive crossmatch can mean a high risk of immediate or severe antibody-mediated injury, depending on the test type and context. Sa maraming situations, hindi itutuloy ang transplant kapag clinically significant ang positive crossmatch, pero final interpretation belongs to the transplant immunology team.

Pinaka-established sensitizing events are blood transfusions, pregnancy including miscarriage, and previous organ transplantation. These exposures can introduce foreign HLA and stimulate the immune system to make antibodies.

Hindi lahat ng taong na-transfuse, nabuntis o na-transplant dati ay magkakaroon ng mataas na PRA. Immune response varies from person to person. Pero kapag may transplant plan, mahalagang alam ng team ang buong sensitization history para ma-interpret nang tama ang HLA testing.

Antibody levels can also change over time. KDIGO recommends updating HLA antibody testing after sensitizing events because a previously negative or low result does not guarantee na hindi magbabago ang profile.

Walang paraan para i-guarantee na hindi kailanman magkakaroon ng HLA antibodies. Pero may isang importanteng modifiable risk: unnecessary blood transfusion.

Ang 2026 KDIGO anemia guideline specifically advises avoiding red-blood-cell transfusions when possible in people with CKD who are eligible for organ transplant, because transfusion can cause allosensitization. Ibig sabihin nito ay dapat ma-manage nang maaga ang anemia with the nephrology team—halimbawa, evaluation of iron deficiency and use of appropriate anemia treatments when indicated—para mabawasan ang need for transfusion.

Importanteng qualifier: hindi dapat tanggihan ang medically necessary o life-saving transfusion para lang mapanatiling mababa ang PRA. Sa severe bleeding, unstable anemia o ibang emergency, transfusion may be necessary. Ang tamang approach ay sabihin sa treating team na transplant candidate ang patient para maisama ang sensitization risk sa decision.

Sabihin agad sa transplant center o HLA laboratory ang date at type of transfusion. KDIGO notes that new HLA antibodies can appear after sensitizing events, so additional testing may be needed rather than waiting for the next routine sample.

Kung nasa transplant waiting list, mahalagang updated ang serum samples dahil ginagamit ang antibody information sa virtual crossmatch, donor selection at immunologic risk assessment.

Huwag umasa na special processing of blood completely removes sensitization risk. The 2026 KDIGO anemia guideline notes that strategies such as washed red cells have not consistently shown elimination of HLA sensitization risk.

Hindi ibig sabihin na tapos na ang transplant journey. A sensitized patient may still receive a transplant if a compatible donor can be found.

Sa living donation, puwedeng pag-usapan sa transplant center ang kidney paired donation or donor exchange kung available at kung incompatible ang original donor-recipient pair. Sa deceased donation, updated HLA antibody profiling helps identify donors whose HLA antigens are not targeted by the candidate's antibodies.

Selected highly sensitized patients may be evaluated for HLA-incompatible transplant or desensitization strategies such as plasmapheresis and immunomodulatory treatment, but these are specialist decisions with variable protocols, costs and risks. Desensitization is not automatically needed for every patient with antibodies.

Pagkatapos ng transplant, ang pinaka-importanteng modifiable factor ay consistent adherence sa anti-rejection medicines. Under-immunosuppression—whether from missed doses or medically directed reduction—can be associated with development of de novo DSA.

Hindi ibig sabihin na dapat dagdagan o baguhin ang immunosuppression nang kusa. Sobrang immunosuppression can also cause serious infection and other complications. Ang transplant team ang nagba-balance ng dose based on drug levels, kidney function, rejection risk and side effects.

Current European consensus recommends evaluating maintenance therapy and adherence when de novo DSA is detected; further treatment decisions may require kidney biopsy and broader clinical assessment.

Ang HLA antibody profile affects which donors are safe and compatible. The higher and broader the sensitization, the harder it can be to find a donor who does not carry an HLA target recognized by the recipient.

That is why preventing avoidable sensitization before transplant, keeping PRA/cPRA and HLA antibody testing updated, and protecting the graft from de novo DSA after transplant are all part of the same goal: increase the chance of finding a compatible kidney and reduce antibody-mediated rejection risk.

The key is not to chase a 'zero PRA' number at all costs. The practical goal is to preserve transplant options, avoid unnecessary sensitizing exposures, and let the transplant immunology team interpret the full antibody and donor profile.